Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

GE17-0618-05

Protein G Sepharose™ 4 Fast Flow

Cytiva 17-0618-05, pack of 200 mL

Sinonimo/i:

Fast Flow resin, Antibody purification resin, IgG purification resin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
41106500
NACRES:
NA.56

ligand

recombinant protein G lacking albumin-binding region

Confezionamento

pack of 200 mL

Produttore/marchio commerciale

Cytiva 17-0618-05

Condizioni di stoccaggio

(20% Ehtanol)

Matrice

4% cross-linked agarose

Diametro medio

90 μm (d50v)

cleaning in place

2-10

working range

3-9

Compatibilità

suitable for bioprocess medium

Temperatura di conservazione

2-8°C

Categorie correlate

Descrizione generale

Protein G Sepharose™ 4 Fast Flow is recombinant protein G coupled to Sepharose™ 4 Fast Flow.

Protein G Sepharose™ 4 Fast Flow has recombinant protein G immobilized by the cyanogen bromide (CNBr) method to Sepharose™ 4 Fast Flow. Protein G exhibit binding specificities that complement Protein A media and binds to the Fc region of IgG from a variety of mammalian species. Protein G Sepharose™ 4 Fast Flow may be used to isolate and purify classes, subclasses and fragments of immunoglobulins from any biological fluid or cell culture medium.

As member of the BioProcess media range, Protein G Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

Caratteristiche e vantaggi

  • Binding specificities that complement Protein A media.
  • Binds a broad range of IgG species and subclasses.
  • Multi-point attachment minimizes ligand leakage.
  • Used in a range of research applications.

Stoccaggio e stabilità

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.

Risultati analitici

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Note legali

Sepharose is a trademark of Cytiva

Pittogrammi

Flame
GHS02

Avvertenze

Warning

Indicazioni di pericolo

H226

Codice della classe di stoccaggio

3 - Flammable liquids

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Monique G P van der Wijst et al.
bioRxiv : the preprint server for biology (2021-03-25)
Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found
Kanika Vanshylla et al.
Cell host & microbe, 29(6), 917-929 (2021-05-14)
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4%
Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
Sara E Vazquez et al.
Journal of clinical immunology, 41(6), 1169-1171 (2021-05-20)
Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Kanika Vanshylla et al.
Cell host & microbe, 30(1), 69-82 (2022-01-02)
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126
Visualizza tutti i documenti correlati

Articoli

Performing a Separation with HiTrap® Protein G HP

Purify monoclonal or polyclonal IgG from serum, cell culture supernatant or ascitic fluid using the HiTrap Protein G HP from Cytiva, an affinity-exclusion chromatography product containing Sepharose-immobilized Protein G.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

Column Packing and Preparation for Affinity Chromatography of Antibodies

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

Converting from Flow Velocity to Volumetric Flow Rates

This page shows how to convert between flow velocity and volumetric flow rate in affinity chromatography of antibodies.

Vedi tutto

Protocolli

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

Sample Preparation for Affinity Chromatography

This page shows how to prepare samples for purification with affinity chromatography.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.